高甘油三酯血症

参考文献

关键文献

Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults. JAMA. 2002 Oct 9;288(14):1723-7. 摘要

Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002 Jan 16;287(3):356-9.全文  摘要

Donnelly KL, Smith CI, Schwartzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005 May;115(5):1343-51. 摘要

Leaf DA, Parker DL, Schaad D. Changes in V02max, physical activity, and body fat with chronic exercise: effects on plasma lipids. Med Sci Sports Exerc. 1997 Sep;29(9):1152-9. 摘要

参考文献

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) - executive summary. JAMA. 2001 May 16;285(19):2486-97. 摘要

2. Kushner PA, Cobble ME. Hypertriglyceridemia: the importance of identifying patients at risk. Postgrad Med. 2016 Nov;128(8):848-58. 摘要

3. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017 Apr;23(Suppl 2):1-87.全文  摘要

4. Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016 Nov;32(11):1263-82.全文  摘要

5. Hegele RA, Ginsberg HN, Chapman MJ, et al.; European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014 Aug;2(8):655-66.全文  摘要

6. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorder. N Engl J Med. 1967 Feb 2;276(5):273-81. 摘要

7. Mostaza JM, Vega GL, Snell P, et al. Abnormal metabolism of free fatty acids in hypertriglyceridemic men: apparent insulin resistance of adipose tissue. J Intern Med. 1998 Apr;243(4):265-74. 摘要

8. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults. JAMA. 2002 Oct 9;288(14):1723-7. 摘要

9. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002 Jan 16;287(3):356-9.全文  摘要

10. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001 Sep 12;286(10):1195-200. 摘要

11. Brunzell JD, Bierman EL. Chylomicronemia syndrome. Med Clin North Am. 1982 Mar;66(2):455-68. 摘要

12. Christian JB, Bourgeois N, Snipes R, et al. Prevalence of severe (500 to 2,000 mg/dl) hypertriglyceridemia in United States adults. Am J Cardiol. 2011 Mar 15;107(6):891-7.全文  摘要

13. Hubert HB, Feinleb M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983 May;67(5):968-77.全文  摘要

14. Zavaroni I, Dall'Aglio E, Alpi O, et al. Evidence for an independent relationship between insulin and concentration of high density lipoprotein cholesterol and triglyceride. Atherosclerosis. 1985 Jun;55(3):259-66. 摘要

15. Tsimihodimos V, Bairaktari E, Tzallas C, et al. The incidence of thyroid function abnormalities in patients attending and outpatient lipids clinic. Thyroid. 1999 Apr;9(4):365-8. 摘要

16. Avram MM, Fein PA, Antignani A, et al. Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis. Am J Med. 1989 Nov;87(5N):55-60N. 摘要

17. Donnelly KL, Smith CI, Schwartzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005 May;115(5):1343-51. 摘要

18. Alves C de A, Lima DS. Cystic fibrosis-related dyslipidemia. J Bras Pneumol. 2008 Oct;34(10):829-37. 摘要

19. SoRelle R. Vascular and lipid syndromes in selected HIV-infected patients. Circulation. 1998 Sep 1;98(9):829-30. 摘要

20. Dron J, Hegele RA. Genetics of triglycerides and the risk of atherosclerosis. Curr Atheroscler Rep. 2017 Jul;19(7):31.全文  摘要

21. Apstein MD, George BC. Serum lipids during the first year following acute spinal cord injury. Metabolism. 1998 Apr;47(4):367-70. 摘要

22. Zakim D, Alexander D, Sleisenger MH. The effect of ethanol on hepatic excretion of triglycerides into plasma. J Clin Invest. 1965;44:1115.

23. Markell MS, Friedman EA. Hyperlipidemia after organ transplantation. Am J Med. 1989 Nov;87(5N):61-67N. 摘要

24. Salazar A, Mana J, Pinto X, et al. Low levels of high-density lipoprotein-cholesterol in patients with active sarcoidosis. Atherosclerosis. 1998 Jan;136(1):133-7. 摘要

25. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in women. Ann Intern Med. 1991 Dec 1;115(11):860-4. 摘要

26. Lardinois CK, Neuman SL. The effect of antihypertensive agents on lipids and lipoproteins. Arch Intern Med. 1988 Jun;148(6):1280-8. 摘要

27. Italian Registry of Antiretroviral Post-exposure Prophylaxis. Effects of short course of antiretroviral agents on serum triglycerides of healthy individuals. AIDS. 2000 Oct 20;14(15):2407-8. 摘要

28. Garg A, Simha V. Update on dyslipidemia. J Clin Endocrinol Metab. 2007 May;92(5):1581-9. 摘要

29. Aggarwal S, Loomba RS, Arora RR. Efficacy of colesevelam on lowering glycemia and lipids. J Cardiovasc Pharmacol. 2012 Feb;59(2):198-205. 摘要

30. Brunzell JD, Hazzard, WR, Porte D Jr, et al. Evidence for a common saturable triglyceride removal mechanism for chylomicron and very low density lipoproteins in man. J Clin Invest. 1973 Jul;52(7):1578-85.全文  摘要

31. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. Arterioscler Thromb. 1992 Aug;12(8):911-9. 摘要

32. Abbasi F, McLaughlin T, Lamendola C, et al. High carbohydrate diets, triglyceride-rich lipoproteins, and coronary heart disease risk. Am J Cardiol. 2000 Jan 1;85(1):45-8. 摘要

33. Cao Y, Mauger DT, Pelkman CL, et al. Effects of moderate (MF) versus lower fat (LF) diets on lipids and lipoproteins: a meta-analysis of clinical trials in subjects with and without diabetes. J Clin Lipidol. 2009 Feb;3(1):19-32. 摘要

34. Oh J, Hegele RA. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis. 2007 Dec;7(12):787-96. 摘要

35. Karalis DG. A review of clinical practice guidelines for the management of hypertriglyceridemia: a focus on high dose omega-3 fatty acids. Adv Ther. 2017 Feb;34(2):300-23.全文  摘要

36. Leaf DA, Parker DL, Schaad D. Changes in V02max, physical activity, and body fat with chronic exercise: effects on plasma lipids. Med Sci Sports Exerc. 1997 Sep;29(9):1152-9. 摘要

37. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.全文  摘要

38. Sacks FM, Lichtenstein AH, Wu JHY, et al. Dietary fats and cardiovascular disease: a Presidential Advisory from the American Heart Association. Circulation. 2017 Jul 18;136(3):e1-23. 摘要

39. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934. 摘要

40. Wu J, Song Y, Li H, et al. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur J Clin Pharmacol. 2009 Dec;65(12):1169-74. 摘要

41. Abourbih S, Filion KB, Joseph L, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med. 2009 Dec;65(12):1169-74. 摘要

42. Ginsberg HN, Elam MB, Lovato LC, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1563-74.全文  摘要

43. Food and Drug Administration. Withdrawal of approval of indications related to the coadministration with statins in application for niacin extended-release tablets and fenofibric acid delayed-release capsules. April 2016 [internet publication].全文

44. Sanders TA, Sullivan DR, Reeve J, et. al. Triglyceride-lowering effects of marine polyunsaturates in patients with hypertriglyceridemia. Arteriosclerosis. 1985 Sep-Oct;5(5):459-65. 摘要

45. Patel AA, Budoff MJ. Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia. Curr Opin Endocrinol Diabetes Obes. 2016 Apr;23(2):145-9. 摘要

46. Yokoyama M, Origasa H; JELIS Investigators. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). Am Heart J. 2003 Oct;146(4):613-20. 摘要

47. Leaf DA. Chylomicronemia and the chylomicronemia syndrome: a practical approach to management. Am J Med. 2008 Jan;121(1):10-2. 摘要

48. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol. 2014 Sep-Oct;8(5):473-88.全文  摘要

49. Connor WE. The dietary treatment of hypertriglyceridemia. Med Clin North Am. 1982 Mar;66(2):485-518.

50. Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011 Sep 1;108(5):682-90. 摘要

51. Kastelein JJ, Maki KC, Susekov A, et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol. 2014 Jan-Feb;8(1):94-106.全文  摘要

52. Rizzo M, Christ ER, Rini GB, et al. The differential effects of thiazolidinediones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance? Expert Opin Pharmacother. 2008 Sep;9(13):2295-303. 摘要

53. Spanheimer R, Betteridge DJ, Tan MH, et al. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14). Am J Cardiol. 2009 Jul 15;104(2):234-9. 摘要

54. Durrington PN. Triglycerides are more important in atherosclerosis than epidemiology has suggested. Arteriosclerosis. 1998 Dec;141 Suppl 1:S57-62. 摘要

55. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996 Apr;3(2):213-9. 摘要

56. Frick MH, Elo O, Haapa K, et al. Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. JAMA. 1987 Nov 12;317(20):1237-45. 摘要

57. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999 Aug 5;341(6):410-8.全文  摘要

内容使用需遵循免责声明